ArticleCureus2026
Short- and Long-Term Prognosis of COVID-19-Associated Versus Non-COVID-19 Takotsubo Cardiomyopathy: A Propensity-Matched Nationwide Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTakotsubo cardiomyopathy (TCM) is a stress-induced cardiomyopathy with transient left ventricular dysfunction, often triggered by acute illness. Coronavirus disease 2019 (COVID-19) has been implicated as a precipitant, but comparative outcome data for COVID-19-related versus non-COVID-19 TCM remain largely limited to the early pandemic, when few effective treatments existed.
methodsWe conducted a retrospective cohort study using the TriNetX database, identifying US adults hospitalized between March 2020 and March 2025 with TCM and created two cohorts: patients with TCM and laboratory-confirmed COVID-19 and patients with TCM without COVID-19, both diagnosed within 14 days of admission. The primary outcome was 30-day all-cause mortality, with secondary 30-day outcomes and one-year mortality also assessed. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated.
resultsOf 16,649 patients (6,367 COVID-19 TCM and 10,282 non-COVID-19 TCM), 5,955 per group remained after propensity score matching. Baseline demographics and comorbidities were well balanced (mean age 66.8 years; 76.8% female). Thirty-day mortality did not differ significantly between COVID-19 and non-COVID-19 TCM (12.0% vs. 11.1%; HR 1.07, 95% CI 0.97-1.19). However, COVID-19 TCM was associated with higher risks of heart failure with reduced ejection fraction (HFrEF) (HR 1.18, 95% CI 1.10-1.26), cardiogenic shock (HR 1.25, 95% CI 1.08-1.46), and ventricular arrhythmias (HR 1.37, 95% CI 1.14-1.64). One-year mortality was significantly higher in the COVID-19 cohort (22.0% vs. 18.3%; HR 1.19, 95% CI 1.10-1.29).
conclusionCOVID-19-associated TCM is not linked to excess short-term mortality but carries higher risks of acute complications and significantly worse one-year survival, highlighting the persistent effects of COVID-19 after an acute infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.